Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Randomized Phase 2 Study of Subcutaneous Daratumumab Plus Carfilzomib/Dexamethasone Versus Carfilzomib/Dexamethasone Alone in Patients with Multiple Myeloma Who Have Been Previously Treated with Intravenous Daratumumab to Evaluate Retreatment (LYNX)

Nizar Bahlis, MD, Jeffrey A. Zonder, Susan Wroblewski, PhD, Ming Qi, MD PhD, Thomas Renaud, Carolyn Jackson, Thierry Facon, MD

Blood (2019) 134 (Supplement_1): 1831.

https://doi.org/10.1182/blood-2019-123486

Published: 2019

Journal Articles

Randomized, Open-Label, Non-Inferiority, Phase 3 Study of Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) Administration in Patients with Relapsed or Refractory Multiple Myeloma: Columba Update

Blood (2019) 134 (Supplement_1): 1865.

https://doi.org/10.1182/blood-2019-122765

Published: 2019

Journal Articles

Randomized, Open-Label, Non-Inferiority, Phase 3 Study of Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) Administration in Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM): Body Weight Subgroup Analysis of Columba

Blood (2019) 134 (Supplement_1): 1906.

https://doi.org/10.1182/blood-2019-122501

Published: 2019

Journal Articles

Facilitated Subcutaneous Immunoglobulin (fSCIG) Administration in Secondary Immune Deficiency (SID) Due to Hematological Malignancies. Efficacy and Safety Real-World Data from a Single-Center in Greece

Maria Dimou, MD PhD, Vasileios Pardalis, MD PhD, Theodoros Iliakis, MD, Aikaterini Bitsani, MD, Ioannis Grafakos, MD, Sotiria Kalyva, PhD, Athanasios Markopoulos, PhD, Marie-Christine Kyrtsonis, MD PhD, Panayiotis Panayiotidis, MD

Blood (2019) 134 (Supplement_1): 3429.

https://doi.org/10.1182/blood-2019-122834

Published: 2019

Journal Articles

Daratumumab (DARA) Plus Lenalidomide Versus Lenalidomide Alone As Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma (NDMM) after Frontline Autologous Stem Cell Transplant (ASCT): Use of Minimal Residual Disease (MRD) As a Novel Primary Endpoint in the Phase 3 Auriga Study

Nina D. Shah, MD, Yana Lutska, PharmD, Huiling Pei, PhD, Ming Qi, MD PhD, Maria Krevvata, PhD, Colleen Kane, PhD VMD, Jon Ukropec, PhD, Thomas S. Lin, MD PhD, Shalaka Hampras, MBBS, PhD MPH

Blood (2019) 134 (Supplement_1): 1829.

https://doi.org/10.1182/blood-2019-122471

Published: 2019

Journal Articles

Daratumumab (DARA) Subcutaneous (SC) Delivery in Relapsed or Refractory Multiple Myeloma (RRMM): Population Pharmacokinetics (PPK) and Exposure-Response (E-R) Analysis

Melody Luo, PhD, Dolly A. Parasrampuria, PhD, Saad Z. Usmani, MD, Maria-Victoria Mateos, Hareth Nahi, MD PhD, Christoph Heuck, Ming Qi, MD PhD, Steven Sun, Pamela L. Clemens, PhD, Honghui Zhou, Yu-Nien (Tom) Sun, PhD, Steven Xu, PhD

Blood (2019) 134 (Supplement_1): 3151.

https://doi.org/10.1182/blood-2019-123405

Published: 2019

Journal Articles

Subcutaneous Daratumumab Plus Standard Treatment Regimens in Patients with Multiple Myeloma across Lines of Therapy: Pleiades Study Update

Blood (2019) 134 (Supplement_1): 3152.

https://doi.org/10.1182/blood-2019-123560

Published: 2019

Journal Articles

Platelet hyaluronidase-2 regulates the early stages of inflammatory disease in colitis

Aaron C. Petrey, Dana R. Obery, Sean P. Kessler, Ash Zawerton, Bruno Flamion, Carol A. de la Motte

Blood (2019) 134 (9): 765–775.

https://doi.org/10.1182/blood.2018893594

Published: 2019

Includes: Supplemental data

Journal Articles

Subcutaneous Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma: Part 2 Safety and Efficacy Update of the Open-Label, Multicenter, Phase 1b Study (PAVO)

Ajai Chari, MD, Maria-Victoria Mateos, MD PhD, Niels WCJ van de Donk, MD PhD, Jonathan L Kaufman, MD, Philippe Moreau, Albert Oriol, MD, Torben Plesner, MD DSc, Lotfi Benboubker, MD, Hareth Nahi, MD PhD, Jie Tang, Peter Hellemans, Brenda Tromp, MSc, Pamela L Clemens, PhD, Andrew Farnsworth, Jesus F San-Miguel, MD PhD, Saad Z. Usmani, MD

Blood (2018) 132 (Supplement 1): 1995.

https://doi.org/10.1182/blood-2018-99-113590

Published: 2018

Journal Articles

Pharmacokinetics (PK) of Subcutaneous Daratumumab in Patients with Relapsed or Refractory (RR) Multiple Myeloma (MM): Primary Clinical Pharmacology Analysis of the Open-Label, Multicenter, Phase 1b Study (PAVO)

Pamela L Clemens, PhD, Steven Xu, PhD, Melody Luo, PhD, Ajai Chari, MD, Saad Z. Usmani, MD, Maria-Victoria Mateos, MD PhD, Niels WCJ van de Donk, MD PhD, Jonathan L Kaufman, MD, Philippe Moreau, Albert Oriol, MD, Torben Plesner, MD DSc, Lotfi Benboubker, MD, Jesus F San-Miguel, MD PhD, X. Yu-Nien Sun, Andrew Farnsworth, Tara Masterson, Peter Hellemans, Ming Qi, MD PhD, Hareth Nahi, MD PhD

Blood (2018) 132 (Supplement 1): 2006.

https://doi.org/10.1182/blood-2018-99-113161

Published: 2018

Journal Articles

Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM): Pavo, an Open-Label, Multicenter, Dose Escalation Phase 1b Study

Ajai Chari, Hareth Nahi, Maria-Victoria Mateos, MD, Henk M. Lokhorst, Jonathan L. Kaufman, MD, Philippe Moreau, MDPhD, Albert Oriol, MD, Torben Plesner, MD, Lotfi Benboubker, MD, Peter Hellemans, Tara Masterson, Pamela L Clemens, Kevin Liu, Jesus F. San-Miguel, MD, Saad Z Usmani, MD

Blood (2017) 130 (Supplement 1): 838.

https://doi.org/10.1182/blood.V130.Suppl_1.838.838

Published: 2017

Journal Articles

Large-Scale, Bioreactor-Generated Expansion of Umbilical Cord Blood Tissue-Derived Mesenchymal Stromal Cells for Clinical Use

Blood (2017) 130 (Supplement 1): 3198.

https://doi.org/10.1182/blood.V130.Suppl_1.3198.3198

Published: 2017

Journal Articles

Open-Label, Multicenter, Dose Escalation Phase 1b Study to Assess the Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (PAVO)

Saad Z Usmani, MD FACP, Hareth Nahi, Maria-Victoria Mateos, MD PhD, Henk M. Lokhorst, MD PhD, Ajai Chari, MD, Jonathan L. Kaufman, MD, Philippe Moreau, Albert Oriol, MD, Torben Plesner, Professor, Lotfi Benboubker, MD PhD, Peter Hellemans, MD, Tara Masterson, Pamela L Clemens, PhD, Tahamtan Ahmadi, MD, Kevin Liu, Jesús San-Miguel, MD PhD

Blood (2016) 128 (22): 1149.

https://doi.org/10.1182/blood.V128.22.1149.1149

Published: 2016

Journal Articles

Platelet hyaluronidase-2: an enzyme that translocates to the surface upon activation to function in extracellular matrix degradation

Sami Albeiroti, Katayoun Ayasoufi, David R. Hill, Bo Shen, Carol A. de la Motte

Blood (2015) 125 (9): 1460–1469.

https://doi.org/10.1182/blood-2014-07-590513

Published: 2015

Includes: Supplemental data

Journal Articles

Protective Mechanisms Of Inter-Alpha Inhibitor Protein On Extracellular Histone Toxicity

Hala Chaaban, MD, Ravi Keshari, PhD, Padmaja Mehta-D'Souza, Robert Silasi-Mansat, PhD, Narcis I. Popescu, PhD, Florea Lupu, PhD

Blood (2013) 122 (21): 19.

https://doi.org/10.1182/blood.V122.21.19.19

Published: 2013

Journal Articles

Gelatinous transformation

Claudiu V. Cotta

Blood (2012) 120 (11): 2166.

https://doi.org/10.1182/blood-2012-02-408815

Published: 2012

Journal Articles

Comparison of B Cell Depletion Mediated by Intravenous (IV) Rituxan® and Rituxan Given Subcutaneous (SC) In Cynomolgus Monkeys

Christopher J Del Nagro, Cheng Ping Mao, Martin Brovarney, Karim Dabbagh, Herbert Birnboeck, Wolfgang F Richter

Blood (2010) 116 (21): 3980.

https://doi.org/10.1182/blood.V116.21.3980.3980

Published: 2010

Journal Articles

A Two-Stage Phase Ib Study to Investigate the Pharmacokinetics, Safety and Tolerability of Subcutaneous Rituximab In Patients with Follicular Lymphoma as Part of Maintenance Treatment

Antonio Salar, Dr., Reda Bouabdallah, Dr., Christine McIntyre, Dr., Pakeeza Sayyed, Dr., Beate Bittner, Dr.

Blood (2010) 116 (21): 2858.

https://doi.org/10.1182/blood.V116.21.2858.2858

Published: 2010

Journal Articles

Genetic variation in hyaluronan metabolism loci is associated with plasma plasminogen activator inhibitor-1 concentration

Matthew B. Lanktree, Christopher T. Johansen, Sonia S. Anand, A. Darlene Davis, Ruby Miller, Salim Yusuf, Robert A. Hegele, on behalf of the SHARE, and SHARE-AP Investigators

Blood (2010) 116 (12): 2160–2163.

https://doi.org/10.1182/blood-2010-02-269902

Published: 2010

Includes: Supplemental data

Journal Articles

Stabilin-1 and Stabilin-2 Are Expressed in Bone Marrow Sinusoidal Endothelial Cells and Mediate Scavenging and Cell Adhesive Functions

Hong Qian, Sophie Johansson, Peter McCourt, Bård Smedsrød, Marja Ekblom, Staffan Johansson

Blood (2008) 112 (11): 1368.

https://doi.org/10.1182/blood.V112.11.1368.1368

Published: 2008

NARROW

Randomized Phase 2 Study of Subcutaneous Daratumumab Plus Carfilzomib/Dexamethasone Versus Carfilzomib/Dexamethasone Alone in Patients with Multiple Myeloma Who Have Been Previously Treated with Intravenous Daratumumab to Evaluate Retreatment (LYNX)

Randomized, Open-Label, Non-Inferiority, Phase 3 Study of Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) Administration in Patients with Relapsed or Refractory Multiple Myeloma: Columba Update

Randomized, Open-Label, Non-Inferiority, Phase 3 Study of Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) Administration in Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM): Body Weight Subgroup Analysis of Columba

Facilitated Subcutaneous Immunoglobulin (fSCIG) Administration in Secondary Immune Deficiency (SID) Due to Hematological Malignancies. Efficacy and Safety Real-World Data from a Single-Center in Greece

Daratumumab (DARA) Plus Lenalidomide Versus Lenalidomide Alone As Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma (NDMM) after Frontline Autologous Stem Cell Transplant (ASCT): Use of Minimal Residual Disease (MRD) As a Novel Primary Endpoint in the Phase 3 Auriga Study

Daratumumab (DARA) Subcutaneous (SC) Delivery in Relapsed or Refractory Multiple Myeloma (RRMM): Population Pharmacokinetics (PPK) and Exposure-Response (E-R) Analysis

Subcutaneous Daratumumab Plus Standard Treatment Regimens in Patients with Multiple Myeloma across Lines of Therapy: Pleiades Study Update

Platelet hyaluronidase-2 regulates the early stages of inflammatory disease in colitis

Subcutaneous Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma: Part 2 Safety and Efficacy Update of the Open-Label, Multicenter, Phase 1b Study (PAVO)

Pharmacokinetics (PK) of Subcutaneous Daratumumab in Patients with Relapsed or Refractory (RR) Multiple Myeloma (MM): Primary Clinical Pharmacology Analysis of the Open-Label, Multicenter, Phase 1b Study (PAVO)

Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM): Pavo, an Open-Label, Multicenter, Dose Escalation Phase 1b Study

Large-Scale, Bioreactor-Generated Expansion of Umbilical Cord Blood Tissue-Derived Mesenchymal Stromal Cells for Clinical Use

Open-Label, Multicenter, Dose Escalation Phase 1b Study to Assess the Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (PAVO)

Platelet hyaluronidase-2: an enzyme that translocates to the surface upon activation to function in extracellular matrix degradation

Protective Mechanisms Of Inter-Alpha Inhibitor Protein On Extracellular Histone Toxicity

Gelatinous transformation

Comparison of B Cell Depletion Mediated by Intravenous (IV) Rituxan® and Rituxan Given Subcutaneous (SC) In Cynomolgus Monkeys

A Two-Stage Phase Ib Study to Investigate the Pharmacokinetics, Safety and Tolerability of Subcutaneous Rituximab In Patients with Follicular Lymphoma as Part of Maintenance Treatment

Genetic variation in hyaluronan metabolism loci is associated with plasma plasminogen activator inhibitor-1 concentration

Stabilin-1 and Stabilin-2 Are Expressed in Bone Marrow Sinusoidal Endothelial Cells and Mediate Scavenging and Cell Adhesive Functions

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only